Please ensure Javascript is enabled for purposes of website accessibility

This Big Leap in Cancer Treatment Could Change the Landscape

By Patrick Bafuma - Updated Apr 1, 2021 at 8:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

TIL therapy looks able to win a large addressable market, and Iovance is the leader of the pack.

Much has been made of chimeric antigen receptor T-cell therapy (CAR T-cell therapy) over the past four to five years. And while the therapy is certainly impressive, it typically only applies to liquid tumors (such as lymphoma, leukemia, or multiple myeloma), which only account for about 10% of new cancer diagnoses in the U.S. Additionally, CAR T-cell therapy often has only a single target (rather than attacking multiple locations on a tumor) and can cause adverse events such as cytokine release syndrome.

Enter tumor infiltrating lymphocytes, or TIL therapy. Unlike CAR T-cell therapy, this approach targets multiple sites on a tumor. It can target solid organ cancers, including melanoma, cervical cancer, head and neck cancer, and lung cancer, and has not had any unexpected off tumor tissue effects to date.

Investors in front of terminals raise their hands in celebration.

Image source: Getty Images.

The company with the therapy furthest along in trials is Iovance Biotherapeutics (IOVA 2.30%). The company's management team believes TIL therapy "represents a highly differentiated, personalized, and targeted immunotherapy" for treating the 1.6 million new cases of solid tumors in the U.S. annually, and the company is setting a high bar with excellent data thus far.

Promising data readouts 

While the company has no approved drugs as of yet, Iovance's phase 2 data for metastatic melanoma is trouncing current standards of care in clinical trials. Current metastatic melanoma treatments have an overall response rate of only 4% to 10%, with overall survival of just seven to eight months.  

Last year, Iovance showcased phase 2 data for Lifileucel, its lead TIL therapy for metastatic melanoma, demonstrating an impressive overall response rate of 36%, an 80% disease control rate, and a median duration of response not yet reached at 28 months of follow-up. All of this is especially impressive given that the participants in the study had received a median of 3.3 other treatments prior to enrollment. Lifileucel's results in a more general population will very likely be even better -- and a lot of patients and investors stand to benefit soon, with pivotal phase 3 data (and a Biologics License Application from the U.S. Food and Drug Administration) expected in 2021.

Iovance is equally impressive in metastatic cervical cancer, where second and third-line treatment have an abysmal 3.4% to 13% overall response rate. Second-line treatments are often different types of treatment (chemotherapy, radiation, immunotherapy, etc) given if a patient's cancer gets worse on the first treatment regimen. Third-line treatment being what is given after a patient's cancer worsens after second-line treatment, and so on and so forth.

For patients who had undergone a mean of 2.4 prior treatments for metastatic cervical cancer, Lifileucel's phase 2 data crushes the current standard of care; a whopping 85% of patients had at least stabilized disease that was no longer getting worse (also known as disease control rate) or, even better, 44% of all patients had reduced tumor burden (also known as a response rate). Median duration of response at 7.4 months of follow up has not yet been reached, meaning that Lifileucel is potentially at least as good if not better than today's overall survival of less than eight months for second-line treatment.

It's not a treatment, it's a platform

A good starting point for a cost comparison may be Gilead Sciences' (GILD -0.83%) Yescarta, a CAR-T therapy approved in October 2017 for patients with certain types of blood cancer (like B-cell lymphoma) who have failed multiple other treatments. Yescarta costs $373,000 for a one-time treatment, according to This seems like a reasonable price comparison as both CAR-T and TIL therapy require exquisite individualized processing before patient treatment.

With just over 10,000 patients for the combined markets of metastatic melanoma and advanced cervical cancer, this equates to a total addressable market of at least $3 billion for Iovance, which is trading at around a $4.3 billion market cap. That sounds rather low for a company that should likely face the FDA for approval for melanoma and cervical cancer treatments by the end of 2022.

But this is just the beginning, as the company also has promising early data for head and neck cancer as well as non-small-cell lung cancer, demonstrating that this could very much become not just a treatment, but an entire platform. Gilead obtained its CAR-T treatment Yescarta by way of acquisition of Kite Pharma, with the intention of Kite's platform eventually positioning the company as an oncology leader. This cost Gilead $11.9 billion to buy Kite Pharma, which at the time of acquisition, had Yescarta pending FDA approval.

Given all of this, with a larger total addressable market and fewer adverse events, one has to wonder how long it will take for big pharma to notice Iovance and its $4.4 billion market cap. If you're a biotech investor looking to add an exciting oncology growth stock to your portfolio, it's well worth your time to take a good look at Iovance.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Iovance Biotherapeutics, Inc. Stock Quote
Iovance Biotherapeutics, Inc.
$15.12 (2.30%) $0.34
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$64.47 (-0.83%) $0.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.